IntrinsicIntrinsic
← All summaries

CorMedix Inc.

CRMD
Financials & Chart →

Business Summary

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The company's primary focus has been the commercialization of DefenCath® (taurolidine and heparin) in the U.S., which was launched in 2024 in the hemodialysis setting. On August 29, 2025, CorMedix acquired Melinta Therapeutics, LLC, significantly expanding its commercial platform and product portfolio to include six marketed, hospital- and clinic-focused infectious disease products, as well as a cardiovascular product.

The company's core business model revolves around generating product revenue from commercial sales of DefenCath to direct customers and distributors, and, since August 29, 2025, from sales of the Melinta Portfolio. Revenue is recognized when customers obtain control of the product, net of estimates for variable consideration such as chargebacks, discounts, returns, rebates, shelf-stock adjustments, and data fees. Additionally, the company recognizes contract revenue from Melinta's license and collaboration agreements, including licensing fees, milestone payments, royalties on sales in licensed territories, and product inventory sales. A partnership with BARDA also contributes contract revenue for research and development services.

DefenCath, an antimicrobial catheter lock solution, is indicated to reduce catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. It was approved by the FDA on November 15, 2023, and commercially launched in April 2024 for inpatient settings and July 2024 for outpatient hemodialysis settings. DefenCath is the largest contributor to the company's net sales and is the first and only FDA-approved antimicrobial CLS in the U.S., having demonstrated a reduction in CRBSI risk by up to 71% in a Phase 3 clinical study. The total annual cost for treating outpatient derived CRBSI episodes and their related complications in the U.S. is up to $2.3 billion , with approximately 80,000 CRBSI episodes and up to 28,000 deaths per year. The company believes its currently contracted customer base for DefenCath represents roughly 60% of the outpatient dialysis centers in the U.S. in terms of the total addressable patient market.

The Melinta Portfolio, acquired on August 29, 2025, includes REZZAYO® (rezafungin for injection), MINOCIN® (minocycline) for Injection, VABOMERE® (meropenem and vaborbactam), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin), BAXDELA® (delafloxacin), and TOPROL-XL® (metoprolol succinate). REZZAYO is a once-weekly IV echinocandin approved for candidemia and invasive candidiasis in adults, with an estimated total addressable market for this indication of approximately $250 million to $350 million . MINOCIN IV is a tetracycline-class antibiotic for serious Gram-positive and Gram-negative infections, including Acinetobacter species. VABOMERE is an IV antibiotic combination for complicated urinary tract infections caused by susceptible Enterobacteriaceae, particularly KPC-producing CRE. ORBACTIV and KIMYRSA are long-acting IV antibiotics for acute bacterial skin and skin structure infections (ABSSSI), offering single-dose administration. BAXDELA is a novel fluoroquinolone for ABSSSI or community-acquired bacterial pneumonia (CABP). TOPROL-XL is a cardioselective beta-blocker for hypertension, a mature product with broad generic availability.

For the fiscal year ended December 31, 2025, CorMedix reported total revenue of $311.709 million , a significant increase from $43.472 million in 2024, representing a 617% increase. Product sales, net, were $304.344 million in 2025, up from $43.472 million in 2024, a 600% increase. DefenCath sales contributed $258.813 million in 2025, while the Melinta Portfolio contributed $45.531 million in product sales from the acquisition date. Contract revenue for 2025 was $7.365 million , primarily from the BARDA agreement ($4.2 million ) and Melinta's licensing agreements ($3.2 million ). Cost of revenues increased to $22.089 million in 2025 from $3.034 million in 2024, a 628% increase. Amortization of intangibles was $13.872 million in 2025, up from $0.156 million in 2024, an 8,792% increase, primarily due to the Melinta acquisition. Gross profit for 2025 was $275.748 million , compared to $40.282 million in 2024, a 585% increase. Operating expenses totaled $125.607 million in 2025, up 101% from $62.638 million in 2024. This resulted in income from operations of $150.141 million in 2025, a substantial improvement from a loss of $22.356 million in 2024. Net income for 2025 was $163.055 million , compared to a net loss of $17.930 million in 2024. Basic EPS was $2.25 and diluted EPS was $2.04 in 2025, compared to a basic and diluted EPS of $(0.30) in 2024. Cash and cash equivalents were $144.837 million as of December 31, 2025, compared to $40.651 million as of December 31, 2024. Total debt, represented by convertible senior notes, was $144.626 million net of deferred financing costs as of December 31, 2025.

The significant operational development during the period was the acquisition of Melinta Therapeutics, LLC on August 29, 2025, for a total consideration of $453.668 million , which included $285.292 million in cash, $23.219 million to acquire Toprol XL product rights, and 3.3 million common shares of the company. This acquisition expanded the company's commercial platform and product portfolio. Additionally, CorMedix initiated a Phase 3 clinical study in the second quarter of 2025 to assess DefenCath's safety and efficacy in reducing CLABSIs in adult patients receiving TPN via CVC, with expected completion in the first half of 2027. The company also initiated its post-marketing pediatric hemodialysis study for DefenCath in 2025. In December 2025, data from an interim analysis of a retrospective, real-world evidence study indicated a 70% reduction in annualized hospitalizations due to CRBSI when dialysis-patient catheters are locked with DefenCath. The company also terminated its three-year agreement with Syneos Health Commercial Services, LLC, effective October 1, 2025, with services completed by December 31, 2025.

Business Outlook

Management anticipates a corresponding reduction to the net pricing for DefenCath for the third and fourth quarters of 2026 due to the transition from TDAPA reimbursement to a post-TDAPA add-on adjustment, which will be $2.37 for that period. However, if CMS utilizes the same methodology to calculate the 2027 post-TDAPA Add-On Adjustment, effective January 1, 2027, the estimated value of the Add-On Adjustment is expected to be three to five-times higher than that granted for the third and fourth quarters of 2026, potentially resulting in higher DefenCath sales prices in 2027 relative to the second half of 2026. After January 1, 2027, the post-TDAPA Add-On Payment will be reassessed again and be made effective on January 1, 2028, and January 1, 2029, covering the three-year period through June 30, 2029.

A key growth area for DefenCath is the pursuit of expanded indications. In the second quarter of 2025, the company initiated a Phase 3 clinical study assessing DefenCath's safety and efficacy in reducing CLABSIs in adult patients receiving Total Parenteral Nutrition (TPN) via CVC. This study is expected to complete in the first half of 2027. The total addressable market for TPN is estimated to be between $500 million and $750 million in the inpatient and home infusion settings, equating to more than 4.5 million potential infusions. Additionally, the company initiated a post-marketing pediatric hemodialysis study in 2025, which, if granted pediatric exclusivity, could provide an additional six months of exclusivity for DefenCath, extending its total marketing exclusivity period to 10.5 years . The Expanded Access Program (EAP) for DefenCath, launched in 2024, aims to provide access to a broader population of adult and pediatric patients using CVCs for various serious medical conditions.

Another significant growth driver is the potential prophylaxis indication for REZZAYO. The ReSPECT clinical trial, a Phase III study evaluating REZZAYO for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation, completed enrollment in September 2025, with top-line data expected in the second quarter of 2026. The total addressable market for antifungal prophylaxis in the U.S. is estimated to be greater than $2 billion .

Operationally, the company is undertaking ongoing technology transfers for the Melinta Portfolio, aiming to reduce costs of goods sold and onshore the manufacture of several products, with expected completion over the next two to three years. The company also has a partnership with BARDA to advance BAXDELA and VABOMERE for pediatric use and BAXDELA against certain biothreat pathogens. BARDA has awarded a total of $47.5 million in funding, with the potential for an additional $97.1 million , totaling up to $144.6 million if all options are exercised, and the contract is expected to continue through 2034.

For capital allocation, the company received net proceeds of approximately $82.4 million from a public offering of common stock in June 2025 and $144.3 million from the issuance of $150.0 million aggregate principal amount of convertible senior notes due 2030 in August 2025. As of December 31, 2025, $22.1 million of common stock remains available for potential sale under the ATM program, and there is $15.0 million of remaining capacity under the 2024 Shelf Registration Statement for the issuance of company securities. The company expects to continue to fund operations from cash collections of accounts receivable, cash on hand, cash equivalents, short-term investments, and potential capital raising sources.

Risk Factors

The company faces several material risks, including the significant customer concentration for DefenCath, with sales to its top three customers accounting for 79% of total revenue for the year ended December 31, 2025. Any adverse purchasing decisions by these customers could materially impact revenue. The transition of DefenCath's reimbursement from TDAPA to a post-TDAPA add-on adjustment on July 1, 2026, is expected to significantly decline the level of reimbursement for the third and fourth quarters of 2026, potentially reducing net pricing. There is no assurance that future reimbursement levels will improve. The company is also subject to ongoing patent litigation for MINOCIN IV against Nexus Pharmaceuticals and Gland Pharma, where an adverse outcome could lead to generic entry, increased competition, and decreased sales. Furthermore, the company has identified a material weakness in its internal control over financial reporting as of December 31, 2025, related to the operational effectiveness of reviewing significant, non-routine transactions, which could result in material misstatements if not effectively remediated. The BARDA development contract is subject to ongoing funding decisions by the U.S. Government, and any reduction or discontinuation of funding could materially impact the business. The company also faces general risks inherent in the biopharmaceutical industry, including intense competition, rapid technological change, the potential for new treatment methods or antimicrobial resistance to render products obsolete, and the extensive and evolving regulatory landscape for drug development, approval, and commercialization.

Management Priorities

Management's message to shareholders emphasizes a focus on increasing stockholder value by maximizing the current portfolio, with promotional efforts concentrated on DefenCath, REZZAYO, MINOCIN IV, and VABOMERE. They also prioritize creating additional value through expanded indications for DefenCath in TPN patients and REZZAYO for prophylaxis of invasive fungal infections in immune-compromised patients. The company is actively pursuing business development opportunities that are synergistic with its existing or future sales infrastructure. Management explicitly states that they expect a corresponding reduction to the net pricing for DefenCath for the third and fourth quarters of 2026 due to the transition from TDAPA to post-TDAPA add-on adjustment, which will be $2.37 for that period. However, they estimate that the 2027 post-TDAPA Add-On Adjustment, effective January 1, 2027, could be three to five-times higher than that granted for the second half of 2026, potentially resulting in higher DefenCath sales prices in 2027. The company currently estimates that as of December 31, 2025, it has sufficient cash, cash equivalents, and short-term investments to fund operations for at least twelve months from the issuance of these financial statements.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — DefenCath
  2. [2] Item 1, Business — Market Opportunity
  3. [3] Item 1, Business — Market Opportunity
  4. [4] Item 1, Business — Market Opportunity
  5. [5] Item 1, Business — DefenCath
  6. [6] Item 1, Business — Market Opportunity
  7. [7] Item 7, MD&A — Results of Operations
  8. [8] Item 7, MD&A — Results of Operations
  9. [9] Item 7, MD&A — Results of Operations
  10. [10] Item 7, MD&A — Results of Operations
  11. [11] Item 7, MD&A — Results of Operations
  12. [12] Item 7, MD&A — Results of Operations
  13. [13] Item 7, MD&A — Total Revenue
  14. [14] Item 7, MD&A — Total Revenue
  15. [15] Item 7, MD&A — Results of Operations
  16. [16] Item 7, MD&A — Contract Revenue
  17. [17] Item 7, MD&A — Contract Revenue
  18. [18] Item 7, MD&A — Results of Operations
  19. [19] Item 7, MD&A — Results of Operations
  20. [20] Item 7, MD&A — Results of Operations
  21. [21] Item 7, MD&A — Results of Operations
  22. [22] Item 7, MD&A — Results of Operations
  23. [23] Item 7, MD&A — Results of Operations
  24. [24] Item 7, MD&A — Results of Operations
  25. [25] Item 7, MD&A — Results of Operations
  26. [26] Item 7, MD&A — Results of Operations
  27. [27] Item 7, MD&A — Results of Operations
  28. [28] Item 7, MD&A — Results of Operations
  29. [29] Item 7, MD&A — Results of Operations
  30. [30] Item 7, MD&A — Results of Operations
  31. [31] Item 7, MD&A — Results of Operations
  32. [32] Item 7, MD&A — Results of Operations
  33. [33] Item 7, MD&A — Results of Operations
  34. [34] Item 7, MD&A — Results of Operations
  35. [35] Item 7, MD&A — Results of Operations
  36. [36] Item 7, MD&A — Results of Operations
  37. [37] Item 7, MD&A — Liquidity and Capital Resources
  38. [38] Item 7, MD&A — Liquidity and Capital Resources
  39. [39] Item 7, MD&A — Convertible Notes Offering
  40. [40] Item 3, Notes to Consolidated Financial Statements — Acquisition of Melinta
  41. [41] Item 3, Notes to Consolidated Financial Statements — Summary of Consideration Transferred
  42. [42] Item 3, Notes to Consolidated Financial Statements — Summary of Consideration Transferred
  43. [43] Item 3, Notes to Consolidated Financial Statements — Summary of Consideration Transferred
  44. [44] Item 1, Business — DefenCath
  45. [45] Item 7, MD&A — Overview
  46. [46] Item 1, Business — Additional Indications
  47. [47] Item 1, Business — Additional Indications
  48. [48] Item 1, Business — Additional Indications
  49. [49] Item 1, Business — Additional Indications
  50. [50] Item 1, Business — Biomedical Advanced Research and Development Authority Contract
  51. [51] Item 1, Business — Biomedical Advanced Research and Development Authority Contract
  52. [52] Item 1, Business — Biomedical Advanced Research and Development Authority Contract
  53. [53] Item 7, MD&A — Follow-On Offering
  54. [54] Item 7, MD&A — Convertible Notes Offering
  55. [55] Item 7, MD&A — Convertible Notes Offering
  56. [56] Item 7, MD&A — Funding Requirements and Liquidity
  57. [57] Item 7, MD&A — Funding Requirements and Liquidity
  58. [58] Item 1A, Risk Factors — Risks Related to the Development and Commercialization of DefenCath
  59. [59] Item 7, MD&A — Overview

Analysis on 5/22/2026